Fewer than 10% of patients who could benefit from GLP-1 drugs including Wegovy have access to them, states the World Health Organization as it issues its initial advice on the therapies.
With in excess of 1,000,000,000 people worldwide now obese, it is advocating for broader and more equitable access to GLP-1 medication.
Per projections, more than two billion will be living with obesity by 2030 unless action is taken.
"The latest guidelines recognises that obesity is a long-term condition that can be treated with comprehensive and continuous care," said its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are significant hurdles to universal access to the treatments that can aid individuals in losing considerable body mass, notes the body.
Skinny Jab Supply Crisis
Despite the current most favorable outlook, the manufacturing of GLP-1 therapies might only reach approximately 100 million people – fewer than 10% of the global need, per the health organization.
The recommendation encourages governments and firms to increase access, through strategies including licensing agreements.
Exclusive production rights on the active ingredient – the main ingredient of the drug Wegovy – is scheduled to end in multiple countries in 2026.
The Way Obesity Jabs Operate
These medications mimick a biological compound to slow digestion, suppress the appetite and boost feelings of fullness so users reduce food intake.
Individuals commonly see weight reduction in the initial weeks of commencing the weekly injections.
Studies points to people may see weight return a year later of discontinuing the medication, because their typical appetite return.
To be above a healthy weight increases your chance for developing diseases, like diabetes, heart disease, stroke, and specific malignancies.
Excess weight impacts individuals in every country and was associated with 3.7 million deaths worldwide in 2024, as per the WHO.
